

**ASX ANNOUNCEMENT****29 August 2023****Notice of date of AGM and other relevant dates**

---

**29 August 2023** – Pursuant to ASX Listing Rule 3.13.1, Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**):

<b>Date &amp; time for AGM</b>	Thursday, 26 October 2023 at 10.00am (Melbourne time)
<b>Date of Notice of Meeting dispatch</b>	Thursday, 21 September 2023
<b>Last date for receipt of nominations as a director</b>	Thursday, 7 September 2023

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting, will be provided in the Notice of Meeting.

The Company's Appendix 4E, together with the FY 2023 Annual Report were released to the ASX on 28 August 2023 and can be accessed and downloaded from the Company's website [here](#).

Shareholders may obtain a hard copy of the Annual Report by emailing a request to the Company at [communications@canngrouponlimited.com](mailto:communications@canngrouponlimited.com).

The Company looks forward to shareholders participating at this year's AGM.

**Authorised for release by Deborah Ambrosini, Company Secretary, Cann Group Limited.**

**For all media enquiries please contact:**

Jackson Paine  
Corporate Communications Manager  
+61 439 492 955  
[jackson.paine@canngrouponlimited.com](mailto:jackson.paine@canngrouponlimited.com)

**For all other information please contact:**

Peter Koetsier  
CEO  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Deborah Ambrosini  
CFO and Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[deborah.ambrosini@canngrouponlimited.com](mailto:deborah.ambrosini@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)